WNT2 and neoplasm: Preclinical studies using human MPM cell lines have shown that WNT2 inhibition via siRNA or monoclonal antibodies induces tumor programmed cell death, even in β-catenin-independent pathways, suggesting a noncanonical role of WNT2 in cell survival.